# Seed 2.0 Code — deep_reasoning/ethical_dilemma_structured

- model_id: `bytedance-seed/seed-2.0-code`
- success: True  | final: 8.52 | quality: 10.0
- latency_total: 40.224s | tokens_per_second: 50.9
- input_tokens: 225 | output_tokens: 2048

## Entrada exacta (lo que recibió el modelo)

**user:**

Una startup de IA tiene un modelo que puede detectar cancer con 95% de precision.
Sin embargo:
- El 5% de falsos positivos causa ansiedad severa y procedimientos innecesarios
- El modelo funciona peor en personas de piel oscura (90% precision vs 97% en piel clara)
- Lanzar ahora salvaria vidas pero con sesgo conocido
- Esperar 6 meses para corregir el sesgo significa que gente morira mientras tanto

El board te pide una recomendacion. Estructura tu analisis:
1. Identifica a todos los stakeholders afectados
2. Analiza los trade-offs cuantitativamente
3. Proporciona 3 opciones con pros/contras de cada una
4. Da tu recomendacion final con justificacion

No busques la respuesta "correcta" - busca la mejor argumentada.


## Respuesta completa


Got it, let's tackle this step by step. First, the user wants a structured analysis for the AI startup's board. Let's start with stakeholders—need to be specific, not just "patients." Let's break it down:

1. Stakeholders: Let's list them with their stakes. First, Patients: split by skin tone (light, dark) because the bias affects them differently, also split by *actual cancer status* (true positives, false positives, false negatives) because each has different outcomes. Then, the Startup: legal risk, brand reputation, investor trust, mission. Clinicians: liability, workflow disruption, patient trust. Regulators: FDA/EMA compliance (since it's a medical device), equity mandates. Payers: coverage decisions, cost of unnecessary procedures. Patient Advocacy Groups: equity (like skin cancer orgs for BIPOC), cancer survival orgs. Wait, also maybe the AI team? Their professional reputation, ethical stance. Let's make that clear, not just vague—group by impact level and specific stakes.

2. Quantitative Trade-offs: Need to ground this in real numbers, not just percentages. Let's define a *test population* to make it concrete—say, 100,000 US adults aged 40-64 (high-risk for melanoma, which is skin cancer, fits the skin tone bias). First, *base prevalence of melanoma*: CDC says ~20 per 100,000? Wait no, wait—maybe *screened population*: let's say 100,000 people, with *true cancer prevalence P=0.5%* (500 true cases) because screening populations have higher prevalence than general. Wait, no, let's adjust to split skin tone: let's say the screened population is 70% light skin (LS), 30% dark skin (DS) (US demographic, but maybe adjust for screening access? Wait no, let's keep it controlled for quant: 70k LS, 30k DS.

Now, define metrics properly: *precision* is TP/(TP+FP), but wait the user said "95% precision"—wait, no, sometimes people confuse precision with accuracy, but let's clarify: the user said "95% precision" overall, 90% DS, 97% LS. Let's formalize:

First, let's fix *sensitivity*? Wait no, wait the user said "precision"—but precision is positive predictive value (PPV). Wait, but to get false negatives, we need sensitivity (true positive rate, TPR). Oh, the user mentioned "falsos positivos" (FP) and "gente morirá" (which is false negatives, FN: people with cancer not detected). So we need to bridge precision (PPV) to TPR and FPR (false positive rate) to get numbers.

Wait, let's make a *controlled quant framework* so trade-offs are tangible. Let's:

- Define **Screened Cohort (N=100,000)**:
  - Skin Tone Split: 70,000 Light Skin (LS), 30,000 Dark Skin (DS)
  - True Melanoma Prevalence (per ACS: 0.3% general, 0.6% screening cohort): let's use *0.5% overall*, split as 0.6% LS (since LS has higher melanoma incidence, ACS says yes—LS 20x higher risk than DS? Wait no, ACS says melanoma is more common in LS, but DS have higher mortality because of late detection. Oh, that's a key point! Let's adjust prevalence to reflect real-world:
    - True Cancer Cases (TCC): 400 total (0.4% of 100k):
      - LS TCC: 350 (0.5% of 70k LS, since LS higher incidence)
      - DS TCC: 50 (0.17% of 30k DS, but *DS have 2x higher mortality if undetected*—critical for quant trade-offs)
  - Model Metrics (as given by startup, clarify PPV=precision per user):
    - Overall PPV = 95% → TP/(TP+FP) = 0.95
    - LS PPV = 97%
    - DS PPV = 90%
    - Now, to get FN (deaths), we need *Sensitivity (TPR = TP/TCC)*. Let's assume the startup's model has a *fixed TPR across skin tones? No, wait the bias is in precision, but likely also TPR? Wait no, user said "90% precision vs 97% en piel clara"—so precision (PPV) is the biased metric, but let's set TPR to a realistic value for cancer screening: say *TPR=90% overall* (so 90% of true cancers are detected, FN=10% of TCC). Wait, but let's tie PPV to FPR (false positive rate = FP/non-TCC) using Bayes' theorem, because PPV depends on prevalence.

Bayes' Theorem for PPV: PPV = (TPR * P) / (TPR * P + FPR * (1-P))

We can solve for FPR, which is the rate of false positives (causes anxiety, unnecessary procedures).

Let's compute for EACH GROUP:

First, **Light Skin (LS)**:
- P (prevalence) = 350/70,000 = 0.005 (0.5%)
- PPV_LS = 97% = 0.97
- TPR_LS = Let's assume TPR is 92%? Wait no, let's pick TPR as 90% *across groups* first, then adjust if needed. Wait, no—let's use the given PPV to find FPR, which is what causes the harm (falsos positivos).

LS FPR calculation:
0.97 = (TPR * 0.005) / (TPR * 0.005 + FPR_LS * 0.995)
Let's set TPR = 90% (standard for good cancer screening models) → 0.9
0.97 = (0.9*0.005) / (0.0045 + 0.995 FPR_LS)
0.97*(0.0045 + 0.995 FPR_LS) = 0.0045
0.004365 + 0.96515 FPR_LS = 0.0045
0.96515 FPR_LS = 0.000135
FPR_LS ≈ 0.00014 (0.014%) → SUPER low false positives for LS.

Now **Dark Skin (DS)**:
- P (prevalence) = 50/30,000 ≈ 0.00167 (0.167%)
- PPV_DS = 90% = 0.9
- TPR_DS = Let's use the same TPR? Wait, but if the model is worse on DS, maybe TPR is lower? Let's say TPR_DS = 80% (since precision is lower, likely both PPV and TPR are worse—user said "funciona peor", so let's make that quantifiable. Because if TPR is lower, FN are higher, which means more deaths for DS.

Wait, let's adjust TPR to reflect "peor rendimiento":
- TPR_LS = 95% (so LS FN = 350 * 0.05 = 17 FN)
- TPR_DS = 80% (so DS FN = 50 * 0.2 = 10 FN)
- Now recalculate FPR for each group using Bayes, since PPV is given:

**LS Quant Numbers (N=70k, TCC=350, TPR=95%, PPV=97%)**:
- TP_LS = 350 * 0.95 = 332.5 ≈ 333
- FN_LS = 350 - 333 = 17 (these are LS people who die, since FN = undiagnosed cancer)
- PPV_LS = TP/(TP+FP) = 0.97 → FP_LS = (TP_LS / 0.97) - TP_LS ≈ (333/0.97) - 333 ≈ 343 - 333 = 10 (false positives for LS: 10 people with anxiety/unnecessary procedures)

**DS Quant Numbers (N=30k, TCC=50, TPR=80%, PPV=90%)**:
- TP_DS = 50 * 0.8 = 40
- FN_DS = 50 - 40 = 1